Sumitomo Mitsui Trust Holdings Inc. Decreases Stock Position in COMPASS Pathways plc (NASDAQ:CMPS)

Sumitomo Mitsui Trust Holdings Inc. cut its holdings in COMPASS Pathways plc (NASDAQ:CMPS) by 7.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 364,962 shares of the company’s stock after selling 27,370 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 0.59% of COMPASS Pathways worth $3,193,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CMPS. Bailard Inc. acquired a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $88,000. TAP Consulting LLC boosted its stake in shares of COMPASS Pathways by 14.7% during the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after purchasing an additional 1,645 shares during the last quarter. AE Wealth Management LLC acquired a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $106,000. Raymond James & Associates acquired a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $205,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $597,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CMPS has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a research report on Thursday, April 18th. Morgan Stanley initiated coverage on shares of COMPASS Pathways in a research report on Monday, April 1st. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of COMPASS Pathways in a research report on Friday, March 1st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $47.40.

Insider Activity at COMPASS Pathways

In related news, major shareholder George Jay Goldsmith sold 23,881 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total value of $203,704.93. Following the transaction, the insider now owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, major shareholder George Jay Goldsmith sold 23,881 shares of COMPASS Pathways stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total transaction of $203,704.93. Following the sale, the insider now owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ekaterina Malievskaia sold 25,750 shares of COMPASS Pathways stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $8.65, for a total transaction of $222,737.50. Following the sale, the insider now owns 4,036,154 shares in the company, valued at approximately $34,912,732.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,601 shares of company stock worth $1,338,911. Company insiders own 4.25% of the company’s stock.

COMPASS Pathways Trading Down 1.8 %

NASDAQ CMPS opened at $8.10 on Thursday. COMPASS Pathways plc has a one year low of $5.01 and a one year high of $12.75. The company’s 50 day moving average price is $9.79 and its 200 day moving average price is $8.40. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The firm has a market capitalization of $501.71 million, a price-to-earnings ratio of -3.39 and a beta of 2.48.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, sell-side analysts predict that COMPASS Pathways plc will post -2.4 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.